Turning Point Brands - Q3 2026 Earnings - TURNING POINT BRANDS INC

Financial Performance:

• Consolidated net sales reached $151 million, up 27% year-over-year (YoY), driven primarily by the Modern Oral segment.
• Modern Oral net sales surged 103% YoY and 9% sequentially, accounting for 49% of total revenue compared to 31% in Q3 2025; gross sales for the segment were $94 million (up 114% YoY).
• Stokers segment net sales grew 52% YoY to $114 million (75% of consolidated sales); Modern Oral contributed $74 million, while heritage Stokers brands grew 3% YoY to $39 million.
• ZigZag segment net sales declined 15% YoY to $37 million.
• Gross profit was $85 million (up 21% YoY) with a gross margin of 56%, slightly down sequentially when normalized for tariff refunds.
• Adjusted EBITDA declined 41% YoY to $18 million due to increased sales and marketing investments; however, it increased 21% sequentially to $3.5 million based on higher gross profit and reduced SG&A.
• SG&A was $75 million, down nearly $2 million sequentially as the company scaled back marketing initiatives with lower returns.
• Free cash flow was $3.5 million; ending cash balance was $251 million.
• Capital allocation included $10 million in stock repurchases during the quarter.

Guidance and Future Outlook:

• Management reaffirmed full-year 2026 outlook provided on September 21: Modern Oral net sales of $260–$270 million and gross sales of $330–$350 million.
• Full-year adjusted EBITDA guidance remains $70–$80 million; effective tax rate expected between 23–26%.
• Fourth-quarter guidance implies a wide range for EBITDA ($70–$80M annualized) reflecting potential quarterly volatility of $2–$3 million due to timing and investment cadence.
• Capital expenditures for Q4 estimated at $1–$2 million (excluding Modern Oral projects), with an additional $3.5 million expected for PMTA support.
• U.S. manufacturing is expected to commence in 2027, pending FDA PMTA approval and facility upgrades.
• Management expects 2027 to feature wider distribution for "Free" in chain accounts and the rollout of "ALP" into chain accounts following spring shelf resets, positioning for long-term growth.

Business Segments and Product Lines:

• Modern Oral: The primary growth driver; both "Free" (chain-focused) and "ALP" (independent/regional-focused) are gaining traction. "Free" is on track to increase chain store count by >70% in 2026.
• Stokers: Heritage brands remain stable; "Stokers MST" is outperforming the category, while loose leaf declined as anticipated.
• ZigZag: Focus remains on core rolling papers with acceleration in cones and wraps; sales remain stable despite the 15% YoY decline, driven by "non-measured" channels (bodegas/smoke shops) not captured in standard data sets.
• Product Innovation: "Free Labs" introduced limited edition flavors based on consumer feedback; "ALP" launched the "New Frontier Collection" with three top-requested flavors.
• Infrastructure: Ongoing investment in Salesforce expansion, retail execution, and domestic manufacturing capabilities to support scaling.

Market and Competitive Landscape:

• The Modern Oral category is maturing, with a "calling of the herd" expected where smaller competitors may be weeded out, leaving a handful of dominant brands (including Free and ALP).
• Chain accounts now represent the majority of category volume; securing placements in national chains is critical for durable brand growth.
• Management believes Free and ALP have a strong competitive moat to become "ubiquitously distributed" brands across the U.S.
• Shift in consumer behavior: billions in cigarette revenue are shifting to modern oral forms, presenting a massive opportunity for market share capture without cannibalizing high-margin cigarette sales.

Risks and Challenges:

• Regulatory: Final approval timing for PMTAs remains a key dependency for the 2027 manufacturing ramp-up; FDA guidance revisions require a dual-track submission strategy to accommodate U.S. manufacturing.
• Margin Compression: Near-term EBITDA is suppressed due to aggressive reinvestment in distribution, marketing, and infrastructure required to build long-term brand value.
• Channel Opacity: ZigZag sales volatility is partly attributed to volume moving through non-measured channels (e.g., bodegas, smoke shops) that do not report to standard retail data sets.
• Timing Uncertainty: End-of-year seasonality and retail buyer loading patterns can shift volume into January, creating short-term forecast variance.

Management Commentary and Tone:

• Tone: Highly confident and bullish on the strategic transformation; CEO David Glasek (newly in role) expressed excitement about the "transformational opportunity."
• Strategy: Emphasis on "early innings" for both brands in brick-and-mortar, despite strong sequential growth; committed to a patient capital allocation approach to capture long-term annuity value.
• Discipline: Management highlighted flexibility in SG&A, scaling back low-ROI spend while doubling down on high-visibility retail execution and merchandising.

Analyst Questions and Answers:

• Seasonality/Guidance: Analysts questioned Q4 Modern Oral guidance; management attributed the range to timing of retailer loading and holiday uncertainty rather than weakening demand, noting strong consumer pull and wholesale data.
• Manufacturing Timeline: Clarified that while 2027 is the target, the exact date depends on FDA PMTA approval; dual-track filing (PMTA-1 for current site, PMTA-2 for new US site) is being used to de-risk the process.
• Distribution Cadence: Confirmed "Free" is ahead of "ALP" in chain negotiations; ALP is currently targeting independents and regional chains, with national chain conversations beginning for a potential spring 2027 rollout.
• Velocity/Repurchase Rates: Positive feedback on velocity in new stores; velocity improves with increased SKU assortment. Early ALP brick-and-mortar performance meets or exceeds expectations.
• M&A/Buybacks: Explicitly stated no M&A plans; focus remains on organic growth. Buybacks remain opportunistic based on share valuation.
• 7-Eleven/Chain Testing: ALP testing in 7-Eleven is performing well with strong facings and turnover; expected to become a meaningful distribution channel in 2027.

Other Key Points:

• CEO transition: David Glasek officially assumed the CEO role, succeeding his previous position as Executive Chairman.
• Strategic Priority: Unshoring the supply chain and establishing domestic manufacturing is a core long-term profitability driver, with facility upgrades underway immediately.
• Brand Portfolio: The two-brand strategy (Free and ALP) allows for distinct channel targeting (chains vs. independents) while maximizing overall category share.
• Marketing Efficiency: Shift toward more selective marketing allocation, focusing on high-return initiatives and integrating partnership branding (e.g., TKO) directly into retail execution.